Showing 4211-4220 of 9729 results for "".
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- Hot Off the Press: Dr. Brooke Jackson’s New Book “Skin Care for Runners” Now Availablehttps://practicaldermatology.com/news/hot-off-the-press-dr-brooke-jacksons-new-book-skin-care-for-runners-now-available/2460875/Durham, NC-based dermatologist Dr. Brooke Jackson’s new book, “Skin Care for Runners”, is now available. The book is the definitive guide to healthy skin and nails for runners—and all athletes. In it, Dr. Jackson, also marathoner, offers tips and
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- New AKN Classification System May Improve Treatmenthttps://practicaldermatology.com/news/new-akn-classification-system-may-improve-treatment/2460852/A new classification system aims to improve the way that Acne Keloidalis Nuchae or AKN is treated. AKN can begin as tiny bumps on the back of the head, typically following a close haircut. However, due to a patient's genetic predisposition, these lesions become unremitt
- Mederma Survey: America's Got Skin Insecuritieshttps://practicaldermatology.com/news/mederma-survey-skin-insecurities-have-major-impact-on-mental-health/2460797/One-third of Americans would not use their smart phone for a year if it meant they could have picture-perfect skin, according to a new survey from Mederma. That’s not all they would do for clear skin either, many would cancel Netflix for life eat only oatmeal for a year, giv
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of
- AAD Survey: One-Third of Americans Flunk Basic Quiz on Skin Cancer and Sun Exposurehttps://practicaldermatology.com/news/aad-survey-one-third-of-americans-flunk-basic-quiz-on-skin-cancer-and-sun-exposure/2460785/One-third of Americans lack a basic understanding of skin cancer and sun protection, according to a recent survey of 1,000 U.S. adults from the American Academy of Dermatology. Shockingly, more than half (53%) of adults are unaware that shade can protect them from the sun’s harmfu
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new